Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

ence Interval: 50 - 91 days), with 29.6% of patients estimated to still be progression-free at four months. Median overall survival was not attained at the time of evaluation.

The most commonly reported adverse events (all grades; >10% patients) in the study included, stomatitis, anorexia, fatigue, rash, nausea, edema peripheral, thrombocytopenia, diarrhea, pruritus, anemia, dysgeusia, vomiting, pyrexia, pneumonitis, constipation and insomnia. Serious adverse events (grade 3 or 4; >3% of patients) included anemia, hyponatremia, raised liver function, fatigue, stomatitis, anorexia, hyperglycemia, hypophosphatemia, ileus and lymphopenia.

About RAD001

RAD001, an oral once-daily inhibitor of mTOR, is an investigational drug being studied in multiple tumor types. In cancer cells, RAD001 provides daily inhibition of mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth.

RAD001 is being studied in multiple cancer types including advanced kidney, breast and neuroendocrine tumors and lymphoma. Currently, RAD001 is under regulatory review in the US and Europe for the treatment of advanced renal cell carcinoma.

The safety and efficacy profile of RAD001 has not yet been established in oncology and there is no guarantee that RAD001 will become commercially available for oncology indications. The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003. Certican is not approved in the US.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "promising," "will," "potential," "may," "committed," "exploring," "believed," "e
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 CHINA ... Senior Care, Rehabilitation Medicine and Healthcare, second to none ... will be held at Shanghai New International Expo Center ... 2015,  Implementation Suggestions on Encouraging Private Capital to Participate ... was jointly issued by the Ministry of Civil Affairs of ...
(Date:3/27/2015)... 2015  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... previously announced registered offering of common shares in ... to the Offering, the Company issued 7,286,432 common shares ... gross proceeds of approximately $1.45 billion. On March 18, ... Exchange Commission a final prospectus supplement to its effective ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/27/2015)... The Monogamy Method - a ... and Jason Rogers has just been released to the ... commotion surrounding the course's launch has caught the attention ... in-depth review of the new program. , "Many women ... lives suddenly start pulling away or expressing interest in ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership ... care provider for the 2015 and 2016 season. As the ... and an athletic trainer for the team throughout each season. ... against the Cleveland Gladiators at Amalie Arena; the game starts ... to us as it gives us the opportunity, to provide ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
Breaking Medicine News(10 mins):Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... Hall of Fame inductees Jackson Browne and Graham Nash ... biggest problem: the health of our peopleWASHINGTON, Jan. 6 ... The Vineeta Foundation, a health and human rights organization, ... the Health for All Blue Diamond Ball will be ...
... FASgen, Inc. is pleased to announce that it has ... Inc. This agreement will give Centocor, Inc. and ... the opportunity to discover and develop novel small molecule ... selective inhibition of Fatty Acid Synthase (FAS) for ...
... 6 Nanotechnology can be described as,the ... changing the way many,industries think of surface ... boat hull, a self-cleaning aircraft or a ... commercial reality using nanotechnology,materials and concepts. Nanovere ...
... Heine and Riester, giving physicians and researchers a one-stop online shop ... ... (Vocus) January 6, 2009 -- ORSupply.com, the largest online marketplace for ... unveiling a new range of otoscopes from Welch Allyn, Heine, and ...
... of member self-scheduling via the Internet , ... ... the industry leader in online customer self-scheduling software, announced several ... base. Major program providers such as Lifecare, Inc., which ...
... Jan. 6 Dr. Siegal,s Direct Nutritionals, ... ) and,worldwide distributor of the internationally-popular Dr. ... products, today announced,that renowned physician, author, and ... attend a grand opening event at the ...
Cached Medicine News:Health News:Health for All Blue Diamond Ball Scheduled to Celebrate Obama's Inauguration 2Health News:FASgen, Inc. Announces Research and License Agreement With Centocor, Inc. 2Health News:Nanotechnology Causes Disruption - Cross Industry 2Health News:ORSupply.com Unveils Largest Selection of Otoscopes Available Anywhere 2Health News:ORSupply.com Unveils Largest Selection of Otoscopes Available Anywhere 3Health News:Online Scheduling Software Is Revolutionizing the Wellness Industry 2Health News:Dr. Sanford Siegal and Weight Loss Success Story Josie Raper, Who Appears on Current People Magazine Cover, to Attend Grand Opening of Dr. Siegal's COOKIE DIET Store in Beverly Hills 2
... Gemini surgical headlight is perfectly balanced and ... and ultra-low-profile and illuminates brilliantly while allowing ... "rams effect." The fully adjustable headband, made ... sit low on the brow, directing the ...
... The use of some micro vascular ... and thrombosis. With use, Stainless steel changes ... is known that pressures above 30g/mm2 may ... are made from titanium which does not ...
... our family of halogen lightsources , ... ... ... two surgeons to work simultaneously from it, while the third lamp is reserved for backup. Designed ...
... Bring the clarity of daylight into ... Xenon Light Source. Designed for a variety ... endoscopic instruments, and video equipment - this ... at 300 watts (6,000o K) for superb ...
Medicine Products: